Prioritizing LDL-C Reduction for Established CVD Patients in Primary Care
Prioritizing LDL-C Reduction for Established CVD Patients in Primary Care
Exploring the Risk of HF Hospitalization or CV Death in HFrEF Patients and a Potential Treatment Option
Exploring the Risk of HF Hospitalization or CV Death in HFrEF Patients and a Potential Treatment Option
Deep Learner: Building AI to Improve Cardiovascular Care
Deep Learner: Building AI to Improve Cardiovascular Care
Confronting the Complexities of Reaching LDL-C Thresholds in Patients with Primary Hyperlipidemia
Confronting the Complexities of Reaching LDL-C Thresholds in Patients with Primary Hyperlipidemia
Primary Hyperlipidemia: Fresh look at an LDL-C Therapy and its Long-Term Data
Primary Hyperlipidemia: Fresh look at an LDL-C Therapy and its Long-Term Data
Overcoming Real World Challenges of LDL-C Management: Looking Beyond Statin Therapy
Overcoming Real World Challenges of LDL-C Management: Looking Beyond Statin Therapy
Reshaping LDL-C Management in Primary Hyperlipidemia with First-in-Class siRNA Therapy
Reshaping LDL-C Management in Primary Hyperlipidemia with First-in-Class siRNA Therapy
The Pathophysiology and Pathoetiology of Heart Failure
The Pathophysiology and Pathoetiology of Heart Failure
The Disease Burden and Epidemiology of Heart Failure
The Disease Burden and Epidemiology of Heart Failure
The Importance of Making an Accurate and Timely Heart Failure Diagnosis
The Importance of Making an Accurate and Timely Heart Failure Diagnosis
Guideline Directed Medical Therapy for the Management of Heart Failure
Guideline Directed Medical Therapy for the Management of Heart Failure
The Interconnectivity of The Cardio-Renal-Metabolic Systems and Associated Comorbidities
The Interconnectivity of The Cardio-Renal-Metabolic Systems and Associated Comorbidities
Critical Considerations of Residual CV Risk in Patients With T2D & ASCVD
Critical Considerations of Residual CV Risk in Patients With T2D & ASCVD
A Treatment for NYHA Class II-III Obstructive HCM Patients
A Treatment for NYHA Class II-III Obstructive HCM Patients
